OT-101
Relapsed/Refractory Cancers (including DIPG)
Key Facts
About Sapu BioScience
Sapu Bioscience is a US-based biotech founded in 2019, focusing on RNA and small molecule therapeutics for oncology and virology. Its core asset is OT-101, a first-in-class anti-TGF-β RNA therapeutic that has demonstrated single-agent activity in relapsed/refractory cancer patients and anti-viral effects against COVID-19. The company leverages deep drug development expertise, holds over 100 patent applications, and is pursuing rare pediatric cancer indications, including a designation for Diffuse Intrinsic Pontine Glioma (DIPG). Sapu is currently pre-revenue and advancing its key programs through clinical trials.
View full company profileAbout Sapu BioScience
Sapu Bioscience is a US-based biotech founded in 2019, focusing on RNA and small molecule therapeutics for oncology and virology. Its core asset is OT-101, a first-in-class anti-TGF-β RNA therapeutic that has demonstrated single-agent activity in relapsed/refractory cancer patients and anti-viral effects against COVID-19. The company leverages deep drug development expertise, holds over 100 patent applications, and is pursuing rare pediatric cancer indications, including a designation for Diffuse Intrinsic Pontine Glioma (DIPG). Sapu is currently pre-revenue and advancing its key programs through clinical trials.
View full company profileAbout Ocumension Therapeutics
A Chinese ophthalmic biotech developing innovative drug delivery technologies for eye diseases including dry eye, glaucoma, and retinal disorders.
View full company profileAbout Oncotelic Therapeutics
Oncotelic Therapeutics is a clinical-stage biotech founded in 2014, advancing a pipeline centered on OT-101, a novel anti-TGF-β RNA therapeutic for cancers like diffuse intrinsic pontine glioma (DIPG) and viral infections including COVID-19. The company leverages a dual strategy of traditional drug development and a novel AI/DAO-driven platform (PDAOAI/Pet2DAO) to enhance research efficiency. With a focus on rare pediatric cancers and a partnership-driven, capital-efficient business model, Oncotelic aims to translate its RNA and small molecule candidates into treatments for significant unmet medical needs.
View full company profile